Who
Bradford D. Dahms
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Jade Biosciences; President and CFO, Theseus Pharmaceuticals; Chief Financial Officer, Cartesian Therapeutics.
In numbers
- Trades disclosed
- 18
- Buys
- 2
- Sells
- 0
- Bought
- $30K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 3 Sep 2019
- Last trade
- 12 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Code A | —37,813 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,875 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,875 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | JBIO Jade BiosciencesBiotechnology | SEC FORM 4 Code A | —37,813 at $0.00 | filing |
| 14 Jul 2025filed 14 Jul 2025 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —526,000 at $0.00 | filing |
| 14 Feb 2024filed 14 Feb 2024 | Theseus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,500 | filing |
| 14 Feb 2024filed 14 Feb 2024 | Theseus Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —332,114 | filing |
| 14 Feb 2024filed 14 Feb 2024 | Theseus Pharmaceuticals | SEC FORM 4 Code U | —8,150.23 | filing |
| 1 Mar 2023filed 2 Mar 2023 | Theseus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 17 Feb 2023filed 21 Feb 2023 | Theseus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Theseus Pharmaceuticals | SEC FORM 4 Bought | $10K1,502.19 at $6.66 | filing |
| 18 Feb 2022filed 23 Feb 2022 | Theseus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 21 Dec 2021filed 22 Dec 2021 | Theseus Pharmaceuticals | SEC FORM 4 Bought | $20K1,970.04 at $10.15 | filing |
| 4 Jan 2021filed 6 Jan 2021 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 4 Jan 2021filed 6 Jan 2021 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 1 Jul 2020filed 6 Jul 2020 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Jan 2020filed 6 Jan 2020 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 3 Sep 2019filed 5 Sep 2019 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.